MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

NCT02137759 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma Multiforme of Brain

Interventions

RADIATION: Standard Radiation Therapy
DRUG: Standard Temozolomide
DRUG: Belinostat

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]